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Abstract
Background: Chronic treatment of glaucoma can present a challenge in patients who lack the means and/or the
discipline to use daily glaucoma medication. We wondered if selective laser trabeculoplasty (SLT) could be a useful
alternative.
Methods: Inclusion criteria: controlled trials comparing efficacy of SLT in adult patients with any form of open
angle glaucoma or ocular hypertension and case reports on side effects of SLT. Two recent meta-analyses identified
eight randomized clinical trials (RCTs) comparing the effect of SLT with medication (prostaglandin analogs) and
with argon laser trabeculoplasty (ALT). We took these eight RCTs as reference base and calculated their success
rates where they were not given. Other articles were added to elaborate on technique and side effects.
Results: Mean intraocular pressure (IOP) reduction after SLT was 3.8–8.0 mmHg after 6 months to 1 year. Mean
success rate of SLT at 6 months to 1 year is 55–82 %. Higher IOP before laser predicts a higher IOP-lowering effect.
In terms of mean IOP reduction, reduction in number of medications and treatment success, the effect of SLT was
found to show no clinically relevant difference from that of contemporary medication (prostaglandin analogs) and
from ALT.
Conclusions: The evidence indicates that SLT is an efficacious primary or adjunctive therapy for treating glaucoma.
Keywords: Glaucoma, Selective laser trabeculoplasty, Review, Open angle glaucoma, Glaucoma treatment, Ocular
hypertension
Background
Glaucoma is a multifactorial disease [1, 2] characterized by
damage to the optic nerve, often caused by an elevated
intraocular pressure (IOP). Worldwide, it is the second
leading cause of blindness, following cataract. It is predicted
that by 2020, 79.6 million people will have glaucoma [3], of
which 74 % will be open angle glaucoma (OAG) [4, 5].
The aim of glaucoma therapy is lowering the IOP in
order to slow down glaucoma progression. Currently, this
goal can be achieved by medication, laser treatment or
surgery [6]. Eye drops are typically the first line of therapy
for glaucoma. However, topical agents and preservatives
in glaucoma medication can produce local and systemic
side effects [1, 4, 5, 7]. Patients must also tolerate repeat
application of drugs and on-going medical costs [8].
Adherence poses a problem [9]. At best, treatment adher-
ence in chronic diseases is estimated to be 75 % [6, 10].
More complex dosing regimens, as common in glaucoma,
result in poorer adherence [4, 8, 9, 11]. Administering top-
ical medications is often problematic for elderly patients
who need assistance to administer the drops or miss the
eye and waste expensive medication [12]. Not properly
using the prescribed drops is a major cause of visual loss in
patients with glaucoma [12].
As an alternative to eye drops, argon laser trabeculoplasty
(ALT) [13, 14] has proven to be a useful treatment. ALT
produces much coagulative damage on biomicroscopy [15]
and probably works mechanically through shrinking the
trabecular meshwork (TM) tissue at the coagulation site
and opening up the adjacent tissue. However, Bylsma et al.
showed that ALT also activates a cellular mechanism that
stimulates TM cell division, rejuvenating the meshwork
[16]. Secretion of interleukins after ALT has also been
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demonstrated, stimulating remodelling of the extracellular
matrix and lowering resistance at the TM [17].
Long-term follow-up showed that after a few years, 68–
95 % of patients returned to a higher IOP. Retreatment
with ALT was found to be ineffective [12, 18, 19].
Selective laser trabeculoplasty (SLT) was launched in
1998 by Latina et al. [20]. A frequency-doubled, Q-
switched, 532 nm Nd:YAG laser is used with pulse duration
of 3 nsec and a spot size of 400 μm. This pulse duration is
too short for melanin to convert the electromagnetic energy
to thermal energy, which means that no heat is generated.
The total energy per μm of spotsize in SLT is more than
6500 times lower than in ALT, which provides a theoretical
basis to consider SLT as a repeatable treatment for lowering
IOP.
In our public hospital, we have a ‘difficult’ population;
there is a tendency for irregular follow up examinations
(no show) because of lack of means and mostly of dis-
cipline to use glaucoma medication, which compromises
therapy. Laser could be a non-invasive treatment that
can partly solve these problems. The question our pa-
tients always ask when we try to motivate them to have
SLT done is: ‘What are my chances that this laser will
work and what problems can I expect from this laser?’
This article sets out to answer those questions in terms
of success rate and side effects of SLT.
Methods
Literature search and trial selection
Studies were identified and retrieved through a system-
atic search of PubMed, Web of Science and Google
Scholar. Keywords used in identifying relevant research
included ‘selective laser trabeculoplasty’, ‘SLT’, ‘glaucoma
treatment’, ‘ocular hypertension’ and ‘side effects of
selective laser trabeculoplasty’.
Inclusion criteria: retrospective and prospective compara-
tive controlled trials studying the effect of SLT in adult pa-
tients with any form of OAG or ocular hypertension
(OHT), with or without medication. We also included
case-reports on side effects of SLT.
Exclusion criteria: studies in which SLT was used as
adjunct for glaucoma operations.
Recently, two meta-analyses were published on SLT. A
meta-analysis by Li et al. [8] identified four randomized
clinical trials (RCTs) comparing the effect of SLT with
medication [21–24]. The meta-analysis of Wong et al.
[25] included these four RCTs and four additional RCTs,
that compared SLT to ALT [26–29]. These eight RCTs
were taken as reference base for our calculations. Other
articles were used to elaborate on technique and side
effects.
The information on author, mean age, sample size,
type of glaucoma, and study design were extracted. We
calculated the success rate if it was not given in the
article and when enough data were present to make this
calculation [21, 22, 26]. Definition of success was a 20 %
lowering of IOP compared to baseline IOP. Where men-
tioned, the incidence of transient post-laser IOP spikes,
redness, anterior chamber reaction, discomfort or other
side effects were recorded.
Review
Mechanism
Cvenkel et al. applied ALT to a part of the eye, and SLT to
another part of the same eye in three patients that were
planned to get an enucleation [15]. After the enucleation,
the anterior segments of the eyes were dissected and
examined. Light microscopy and transmission electron
microscopy showed much less structural changes after
SLT than after ALT. Damaging the pigmented cells of the
TM without mechanical or thermic effect by SLT seemed
to be enough to enhance the outflow through the TM.
This may be a sign that SLT works more at a cellular level,
through stimulation of the formation of healthy TM
tissue, like ALT [16, 17, 30]. Detorakis et al. also found
arguments for a biochemical mechanism with release of
cytokines after laser that possibly attract macrophages and
stimulate phagocytosis of debris in the TM [31]. Both cel-
lular and biomechanical mechanisms can enhance the
outflow capacity of the TM with minimal damage to the
tissue [15, 32].
Characteristics of intervention
In the eight reference RCTs of Wong et al. [25] and Li
et al. [8], 45–102 SLT applications were applied, with a
spot size of 400 μm and power between 0.47 and 1.7 mJ,
with each spot lasting 3 ns. See also Table 1.
In the 2005 study, Nagar et al. [23] randomized
patients to 90, 180, and 360° treatment. The 90° had a
very low success rate at a mean of 10.3 months (34 %).
Although there was no statistically significant difference
in outcome after 180° or 360° of SLT treatment, success
rates were better with 360°. In their trial, Bovell et al.
[26], Liu et al. [27], Rosenfeld et al. [28], and Kent et al.
[29] chose to treat 180° of the TM. Lai et al. [22], Nagar
et al. [23], and Katz et al. [21] treated 360°. Katz et al.
started by treating 360° and performed a 180° treatment
when a second SLT was needed during follow up.
The energy level used is titrated to the degree of tra-
becular pigmentation. The greater the pigmentation, the
less energy is required. To determine the optimal energy
level, the power setting is initially set at 0.6–0.9 mJ and
the energy level is increased by 0.1 mJ until bubble for-
mation (champagne bubbles) is observed. If bubble for-
mation is already noted at the initial energy level, the
laser energy is reduced by 0.1 mJ [20]. An energy level
just below that of bubble formation is then maintained.
In their population of pseudoexfoliative syndrome (PEX)
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Table 1 Baseline characteristics of randomized clinical trials using SLT
Author,
year
Design,
location
Type of glaucoma # eyes
after SLT
Treatment in
control arm
Mean follow-
up (months)
Mean age
(years)
SLT group baseline IOP
(mmHg)
Control group baseline IOP
(mmHg)
Characteristics SLT (extent,
number spots, power)
Lai, 2004
[22]
SC,
China
POAG, OHT 29 medication
(not specified)
60 51.9 ± 14.7 26.8 ± 5.6 26.2 ± 4.2 360°, 100, 1.0 ± 0.1 mJ
Nagar,
2005 [23]
MC, UK POAG, OHT, PEX, PDS 128 medication
(lat)
10.3 63 NA NA 90° (25–30 spots),
180° (48–53 spots),
360° (93–102 spots),
0.8-1.7 mJ
Nagar,
2009 [24]
SC, UK POAG, OHT 20 medication
(lat)
4–6 66.4 26.1 ± 4.0 22.8 ± 4.5 360°, 100 ± 5, 0.8–1.4 mJ
Katz, 2012
[21]
MC, USA POAG, OHT 67 medication
(prost)
6–12 NA 25.0 ± 2.2 (4–6 mth group),
24.5 ± 2.1 (9–12 mth group)
24.5 ± 2.2 (4–6 mth group),
24.7 ± 2.4 (9–12 mth group)
360°, 100, 0.8–1.2 mJ
Bovell,
2011 [26]
SC,
Canada
POAG, PEX, PDS, mix
mech, others
89 ALT 60 69.7 ± 10.52 23.8 ± 4.9 23.48 ± 4.21 180°, 50, 0.47–1.5 mJ
Liu, 2012
[27]
SC,
Canada
POAG, OHT, PEX, PDS,
NTG, juv OAG, mix mech
20 ALT 37 48.7 ± 9.4 19.1 ± 4.5 21.9 ± 4.4 180°, 45–55, 0.7–0.8 mJ
Rosenfeld,
2012 [28]
SC, Israel POAG, OHT, PEX, PDS 22 ALT 12 71.95 25.36 ± 1.83 25.11 ± 2.16 180°, 50–70, 0.8–1.2 mJ
Kent, 2013
[29]
MC,
Canada
PEX 37 ALT 6 72.9 ± 9.86 23.1 ± 4.22 25.2 ± 4.87 180°, 53 ± 3.75, 0.6 mJ
Abbreviations: SC = single centre; MC = multicentre; NA = not available; POAG = primary open angle glaucoma; OHT = ocular hypertension; PDS = pigment dispersion syndrome; PEX = pseudoexfoliation syndrome;
NTG = normal tension glaucoma; juv = juvenile glaucoma; mix mech = mixed mechanism glaucoma; lat = latanoprost; prost = prostaglandin analog
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patients, Kent et al. used a mean energy level of 0.6 mJ
[29] for their population of pseudoexfoliation glaucoma
patients.
Ayala et al. [33] found that higher energy creates a
longer IOP lowering effect after SLT and Lee et al. [34]
also suggested using a higher energy density (number of
spots multiplied by mean energy) to improve SLT out-
come. On the other hand, more energy and more spots
may be associated with more side effects [23] and an in-
creased risk of corneal oedema [35], so caution has to be
taken.
It may be important to bring in mind that the energy
used in SLT is much lower than in ALT. SLT classically
uses around 0,9 mJ of energy [23–25], whereas ALT uses
around 50 mJ (500 mW for 0.1 s) [26–28]. This makes
the energy used by SLT 55 times smaller than in ALT.
The laser spot used in SLT has a diameter of 400 μm
[23–25] or an area of 0.13 mm2. ALT uses a spot of
50 μm [26–28] or an area of 0.002 mm2. The energy in
ALT is thus aimed at an area 64 times smaller than in
SLT. This means that the energy per mm2 of tissue is
3520 times smaller in SLT than in ALT.
Comparison of SLT to medication
The effectiveness of SLT compared to contemporary
medication (prostaglandin analogs) was investigated in a
large meta-analysis by Li et al. [8]. Five prospective studies
were included in their study, four randomized and one
non-randomized. Wong et al. identified the same four
randomized RCTs. We included these four studies, one
published by Lai et al. [22], two by Nagar et al. [23, 24],
and one by Katz et al. [21]. Two of them were single
centre, while the others were multicentre trials, see Table 1.
The number of patients treated with SLT ranged from 20
to 67; the largest trial by Nagar et al. included 128 eyes
[23]. Mean follow up time was short: 4 to 12 months. Lai
[22] and Bovell [26] had a follow up time of 5 years. The
study of Nagar [23] mentioned a range of follow up from
1 to 12 months. In this study, patients were randomized
to medication and 90°, 180°, and 360° of SLT. The second
trial of Nagar et al. [24] was designed to compare the
effect of reduction of IOP fluctuation between SLT and
latanoprost, with a mean follow up of 4 to 6 months. This
study showed a significantly higher baseline IOP in the
latanoprost group, which was adjusted for calculation of
the IOP fluctuation. Baseline IOP was above 24.5 mmHg
in three of the four RCTs (not available in Nagar [23]). No
significant differences in IOP lowering effect could be
found between the medication and the SLT groups.
Comparison of SLT to ALT
Wong et al. [25] conducted a meta-analysis involving all
studies on SLT effect in patients with OAG or OHT.
They included primary open angle glaucoma (POAG),
PEX, pigment dispersion syndrome (PDS), uveitis glau-
coma, juvenile glaucoma, steroid-induced glaucoma, and
normal tension glaucoma. Four RCTs comparing the ef-
ficacy of SLT and ALT were identified. These studies
were conducted between 2011 and 2013, which included
one multicentre and 3 single centre trials. Baseline char-
acteristics are shown in Table 1. The number of patients
treated was again mostly limited (20–37) with one larger
study (89 patients) by Bovell et al. [26]. Liu et al. focused
on younger patients, with a mean age of 48.7 years and a
significantly lower baseline IOP (19.1 mmHg). Rosenfeld
et al. [28] recruited patients that underwent successful
cataract extraction 3–6 months before the study com-
menced. Kent et al. [29] limited their study to patients
with PEX. All studies concluded that the IOP-lowering
effect of SLT was comparable to ALT.
Success rate
The IOP reduction varied from 3.8 to 8.0 mmHg at
6 months to 1 year after SLT (see Table 2). The lowest
reduction of 3.8 mmHg was found in the population of
Liu et al. [27]. This group started with a low mean base-
line IOP (19.1 mmHg). As a higher baseline IOP is pre-
dictive of a greater IOP decrease, a lower response could
be expected.
Five studies used ‘more than 20 % reduction of the
IOP compared to baseline IOP’ as their definition of suc-
cess (Lai et al. [22], Nagar et al. [23, 24], Bovell et al.
[26], Kent et al. [29]). Their success rates at 6 months to
1 year varied from 55 to 82 %. Again, Liu et al. reported
the lowest success rate. This result is in line with trials
that claim SLT can be used to lower IOP in normal ten-
sion glaucoma, but rarely (in 22 % of patients) creates an
IOP reduction of more than 20 % [36]. The success rate
of the group that was treated over 90° of TM by Nagar
was the lowest recorded; this treatment was considered
as insufficient [23]. Lai [22], Katz [21] and Rosenfeld
[28] reported success rates ranging from 75 to 97 % after
6 months to 1 year, but used criteria of success that de-
viated from the others and appear less stringent (IOP
less than 21 mmHg [22], IOP less than 2 mmHg above
target IOP [21] or more than 15 % IOP reduction [28].
Prediction of success of SLT was examined in several
trials and has proven indifferent to: gender, race [23], family
history, other glaucoma risk factors, type and severity of
OAG, TM pigmentation [19, 37], pseudo-exfoliation [18],
number and type of anti-glaucoma medications [22, 38],
previous laser [26, 39], phakic or pseudophakic eyes [40],
patent iridotomy [41], presence of systemic hypertension or
diabetes mellitus [9, 42].
The only variable that predicts a better IOP-lowering ef-
fect after SLT is a higher IOP prior to laser [5, 18, 43, 44].
One study found shortened time to failure with increasing
age [33], but this was not confirmed by others. Lee et al.
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Table 2 Results of the randomized clinical trials using SLT
Author,
year
SLT IOP red (mmHg)
at 6 m—1 y (months)
SLT IOP red (mmHg)
end of study (months)
Control group IOP red
(mmHg) at 6 m—1 y
(months)
Control group IOP red
(mmHg) end of study
(months)
SLT definition of success SLT success rate at
6 m—1 y (%)
(months)
SLT success rate at end
of study (%) (months)
Lai, 2004
[22]
8.0 (12) 8.6 ± 6.7 (60) 7.0 (12) 8.7 ± 6.6 (60) IOP < 21 mmHg 97 72.41 (60)
Nagar,
2005 [23]
NA – NA – >20 % IOP red 90° = 34 –
180° = 65
360° = 82 (10)
Nagar,
2009 [24]
6.2 ± 0.8 (4–6) – 7.8 ± 0.8 (4–6) – >20 % IOP red 75 (4–6) –
Katz, 2012
[21]
6.3 ± 2.7 (12) – 7.0 ± 1.8 (12) – IOP ≤ 2 mmHg above
target IOP + no VF loss ≥ 3
unit
80 (12) –
Bovell,
2011 [26]
6.0 ± 6.1 (12) 7.4 ± 7.3 (60) 6.0 ± 4.8 (12) 6.7 ± 6.6 (60) >20 % IOP red 71 (12) 25 (60)
Liu, 2012
[27]
3.8 (12) 1.8 (24) 2.7 (12) 2.8 (24)a def 1: > 20 % IOP red 55 (12) def 1: 40 (24)a
def 2: IOP < target IOP def 2: 75 (24)a
Rosenfeld,
2012 [28]
4.3 (12) – 3.23 (12) – ≥15 % IOP red 75 (12) –
Kent, 2013
[29]
6.8 (6) – 7.0 (6) – >20 % IOP red 73 (6) –
Abbreviations: IOP red = IOP reduction; m = months; y = year; NA = not available; red = reduction; VF = visual field; def = definition; end of study = when study was longer than 12 months
aResults of Liu et al. [27] at end of study (37 months) were not available
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[34] also found a significant correlation between both eyes
in almost 80 % of treated OAG subjects; success after SLT
in one eye correlates with a higher chance of success in
the other, which has been confirmed by Shazly et al. [45].
Thinner corneas (CCT <555 μm) also seemed to give bet-
ter IOP reduction after SLT [46, 47].
Long term effect
The effect of ALT diminishes over time and the 5-year
success rate is reported to be about 50 % [26]. Long-
term effectiveness of SLT seems to show similar results.
Bovell et al. [26] started with a 71 % success rate at
1 year, which decreased to 52 % at 2 years, 44 % at
3 years, 38 % at 4 years, and 25 % at 5 years. Lai et al.
[22] reported a success rate of 97 % 1 year after SLT and
72 % 5 years after SLT, but as noted; their definition of
success was less stringent (IOP below 21 mmHg).
The usefulness of SLT and its possible cost-efficient
character [12, 48] thus relies upon its repeatability. Hong
et al. [39] published one of the first studies on repeat
SLT. They examined the effect of a second SLT over
360° in patients who underwent an initial 360° SLT that
was successful for more than 6 months but eventually
lost efficacy. They recorded no significant difference be-
tween treatments and equal success rates after the first
and the second SLT. They also compared the group of
patients who had a second SLT after 6 months with a
group that only needed a second SLT after 12 months
and found no differences. They concluded a repeat SLT
could be performed as soon as 6 months after a success-
ful first SLT. Ayala et al. [42] treated only 180° of the
TM and examined if repeat SLT had better results when
it was performed in another area as the first SLT. After a
failed SLT, they randomized patients to receive a second
SLT in the same or in a different area than the first SLT.
This made no difference, which supports the minimal
damage theory.
Side effects of SLT
Redness, discomfort and anterior chamber reaction in
the first week after SLT are very common. Nagar et al.
[23] recorded discomfort and pain in the first week in
6 % of the patients that underwent 90° SLT, 20 % after
180°, and 39 % after 360°. Anterior chamber reaction/
uveitis was present in 31 % of patients after 90° SLT,
41 % after 180°, and 50 % after 360° treatment. These ad-
verse effects are common but much less pronounced
than after ALT [49]. Seven of the RCTs used steroids or
non-steroidal anti-inflammatory drops after SLT to di-
minish the side effects (see Table 3). Katz et al. [21] did
not mention the use of pre- or post laser drops. Other
short lived side effects include headache, photophobia,
corneal abrasion, pigment dispersion and subconjuncti-
val haemorrhage [25].
IOP spike
The transient IOP spike after laser trabeculoplasty is
supposed to be dependent upon the energy used per
pulse and the total energy administered [50]. Since SLT
uses much less energy than ALT, per pulse (0.9 mJ com-
pared to 50 mJ) the IOP-rise is much less common and
less pronounced [26–28, 49]. Still, a short increase of
more than 5 mmHg above baseline IOP was recorded in
4.5–27 % of patients in three of the RCTs (Lai et al. [22],
Nagar et al. [23] and Bovell et al. [26]).
As in ALT [50], a drop of apraclonidine [22, 33, 39,
51–53] or brimonidine [54–56] before and immediately
after SLT can be used to prevent the IOP-spike. Seven of
the RCTs mentioned the use of apraclonidine, ametho-
caine, or brimonidine prior to SLT. If IOP elevation did
occur, it was treated with anti-glaucoma medication.
Corneal changes
Transient corneal thinning and changes in endothelial
cell count seem common after SLT, with recovery to
normal after one month [57, 58]. In the eight RCTs, no
other complications after SLT were noticed. Other stud-
ies reported on some rare corneal changes: two cases of
transient corneal oedema [59] and one case of corneal
decompensation [60] after SLT have been described.
Knickelbein et al. [35] reported 4 cases of corneal
hydrops, a condition characterized by acute corneal
oedema followed by stromal thinning. Their findings
suggest that SLT induces cytokine production and acti-
vation of matrix metalloproteinases, which are also in-
volved in destructive inflammatory responses and can
enhance collagen degeneration by corneal fibroblasts.
Cystoid macular oedema
Two cases of cystoid macular oedema [61, 62] have been
reported, but it is suggested that this kind of complica-
tion is related to previous complicated lens-surgery.
Caution would be needed in patients after compromised
cataract surgery. Other very rare complications that have
been reported include one case of iritis and choroidal ef-
fusion [63] and two cases of hyphema [64] after SLT.
Conclusions
Robust evidence was presented that there is no signifi-
cant difference in IOP lowering effect between medica-
tion and SLT or between ALT and SLT. At 6 months to
1 year, the success rate of SLT varied between 55 and
82 %. Higher baseline IOP is correlated to higher IOP
lowering effect of SLT.
Side effects of SLT are minor. A transient IOP spike is
common. Apraclonidine, amethocaine, or brimonidine
drops can be administered before and immediately after
SLT to counter this IOP rise. More severe side effects
like corneal or macular oedema, peripheral anterior
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Table 3 Side effects mentioned in the randomized clinical trials using SLT
Author, year Drops administered before
SLT
Drops administered after
SLT
Redness First
week
Discomfort First
week
Anterior chamber reaction First
week
Definition IOP
spike
IOP spike
(%)
Other side-
effects
Lai, 2004 [22] apra apra 1x + pred 4x, 7d yes NA yes >5 mmHg 10 none
Nagar, 2005 [23] ameth dex or keto 4x, 5d NA 90° = 6 %;
180° = 20 %;
360° = 39 %
90° = 31 %;
180° = 41 %;
360° = 50 %
≥5 mmHg 90° = 9 %;
180° = 16 %;
360° = 27 %
none
Nagar, 2009 [24] ameth keto 4x, 5d NA NA NA NA NA NA
Katz, 2012 [21] NA NA NA NA NA NA NA none
Bovell, 2011 [26] apra or brim pred 4x, 5d NA NA NA ≥6 mmHg 4.5 NA
Liu, 2012 [27] brim fluoro 4x, 5d NA NA NA NA none none
Rosenfeld, 2012
[28]
apra dex 3x, 7d NA NA NA NA NA none
Kent, 2013 [29] brim + pilo keto 4x, 5d NA NA NA >6 mmHg NA NA
Abbreviations: NA = not available; apra = 1 % apraclonidine; pred = 1 % prednisolone acetate; ameth = 1 % amethocaine; dex = 0.1 % dexamethasone; keto = ketorolac; brim = 0.2 or 0.15 % brimonidine; fluoro = 0.1 %
fluorometholone; pilo = 1 % pilocarpine; 4x = 4 times daily; 5d = for 5 days; 7d = for 7 days
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synechiae, hyphema, severe uveitis or persistent IOP rise
are very rare.
Topics to be addressed in the future
Further investigation is needed to demonstrate if SLT
can be repeated enough to maintain IOP under control
for decades on end. Possibly, the future of SLT lies in a
yearly application of a smaller number of spots, as is
currently under investigation by Gandolfi et al. (Vienna,
SOE meeting, 2015).
In conclusion, SLT may be introduced into glaucoma
management algorithms in two ways. First, as a primary
treatment to patients with OAG, comparable in efficacy
to medication. Second, as a treatment alternative for pa-
tients not controlled with maximally tolerated medica-
tion, before invasive surgery.
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